Lasting Effect Consumer Pharma

Lasting Effect developed a Buccal extended controlled release delivery system. The system is a platform enables topical effect or systemic absorption of active ingredients through transmucosal and sublingual routes, Bypassing first-pass metabolism and offers a greater bioavailability, while maintaining user’s compliance during both wakefulness and sleeping hours. The technology based on patented extended controlled release mechanism, combined with selected taste compounds that generates saliva. Lasting Effect drug delivery system is a platform enables topical effect or systemic absorption of active ingredients through transmucosal route, offers a greater bioavailability, while maintaining user’s compliance during both wakefulness and sleeping hours. The technology based on patented extended controlled release system, combined with selected taste compounds that generates saliva. The saliva dissolves the tablet and the active material loaded on it. The technology enables to load and dissolve a wide range of active materials, including lipophile hydrophobic materials. The platform tablet adhered to the mucosa in the oral cavity, laniary dissolving for up to 8 hours while screening bitter tastes of the active materials. All the inactive materials of the platform are GRAS. Products: 1. Buccal tablet for Xerostomia and Halitosis. Regulation as dietary supplement. Ready to market. 2. Tablet loaded with CBD for Gingivitis - gum inflammation, treatment. The product is in a clinical stage. The tablet loaded with CBD shown a powerful anti-inflammatory effect, inhibiting between 93-96% of Gingivitis causing bacteria's. 3. In development - tablet for Parkinson and cognitive impairments treatment. Unique formulation of antiparkinsonian drugs, which is loaded into the tablet and releases continuously the APIs in the oral cavity, enabling to provide a continues dopaminergic stimulation. Partners: Maccabi HealthCare, Padagis Pharma, OwerCrowd, Kobi Zaharia, Ariel Malik.

Lasting Effect Consumer Pharma has raised $1.85M in total funding across 2 rounds. The company is currently at the Pre-Seed stage. Key investors include MaccabiDent, OurCrowd, Padagis.

Lasting Effect Consumer Pharma was founded in 2020 by David Tavor (Board member, Investors relations), Igal Pikovsky (CEO), Eli Heldman (CTO ).

Lasting Effect Consumer Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Lasting Effect Consumer Pharma is based in Be'er Sheva, Israel, South District.